N/A
N=25
Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
Liver Cancer
Bottom Line
View on ClinicalTrials.gov: NCT04195438 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: CO Output (Ppm) — 2.03 ppm
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- CO Testing Pre/Post Hepatic Resection (Procedure); ABG Testing Pre/Post Hepatic Resection (Diagnostic_test); CT Evaluations (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Maryland, Baltimore
- Primary completion
- Mar 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY CO Output (Ppm) |
3.00 | — |
| PRIMARY ABG (COHb) |
1.54 | — |
| PRIMARY CO Output (Ppm) |
3.00 | — |
| PRIMARY ABG (COHb) |
1.54 | — |
| PRIMARY CO Output (Ppm) |
3.00 | — |
| PRIMARY ABG (COHb) |
1.54 | — |
| SECONDARY Volume (ml) |
170 | — |
Summary
The study will monitor carbon monoxide production in patients undergoing liver resection. Carbon monoxide will be checked from arterial blood gas obtained routinely as a part of the postoperative care as well as from the exhaled air of the patient through a CO detector commercially available and used as smokerlyzer helping people to stop smoking. The results of the surgical resection will be collected from the patient routinely ordered tests after liver resection including pathology of the resected part of the liver, laboratory and radiology tests. The study aims to identify the relationship between CO production and recovery after liver resection. Results of this study may help in predicting and improving results of liver resection.
Eligibility Criteria
Inclusion Criteria
- Patients plan to have partial liver resection for primary liver pathology or metastatic disease.
- Patients able to comprehend and willing to sign the written consent form.
Exclusion Criteria
- Patients age less than 18
- Patients not having pathology proven liver malignancy
- Patient not able to comprehend or sign written consent form.
Data sourced from ClinicalTrials.gov (NCT04195438). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.